Abstracts

PHENOTYPIC SUSCEPTIBILITY TO VRCO7-523LS AND ITS CORRELATES IN THE ACTG A5357 STUDY

Background: VRC07-523LS is a broadly neutralizing anti-HIV-1 envelope monoclonal antibody under investigation in combination with LA-cabotegravir for maintenance of HIV-1 suppression in the AIDS Clinical Trials Group (ACTG) A5357 study. Eligibility for A5357 required susceptibility to VRC07-523LS, defined as half-maximal inhibitory concentration (IC50) ≤ 0.25 μg/mL and a maximum percent inhibition (MPI) > 98% on…

ACE2 SUBSTRATE CLEAVAGE EFFECT ASSOCIATED WITH COVID-19 PATIENT PLASMA IMMUNOGLOBULIN

Background: Many mechanisms responsible for COVID-19 pathogenesis are well-known, but COVID-19 includes features with unclear pathogenesis, like autonomic dysregulation, coagulopathies, and high levels of inflammation. The SARS-CoV-2 spike protein receptor binding domain (RBD) receptor is angiotensin converting enzyme 2 (ACE2). We hypothesized that some COVID-19 patients may develop immunoglobulins (Igs) that have negative molecular image…

SARS-CoV-2 VACCINE EFFECTIVENESS IN A COHORT OF ACTIVE-DUTY US MILITARY PERSONNEL

Background: The US Defense Dept launched its COVID-19 vaccination program in Dec 20. The VIRAMP study was designed to address knowledge gaps in US military personnel including vaccine effectiveness against asymptomatic infection, viral carriage and transmission, and durability of protection. Methods: Military members who had received ≥1 dose of an FDA-authorized COVID-19 vaccine were enrolled…

PK & SAFETY OF ABC/3TC DISPERSIBLE TABLETS & LPV/r GRANULES IN NEONATES: PETITE STUDY

Background: No oral solid fixed-dose combination (FDC) antiretroviral dispersible formulations are available for HIV prevention or treatment from birth. Neonates could benefit from existing pediatric antiretroviral solid formulations. We evaluated the pharmacokinetics (PK) and safety of pediatric ABC/3TC dispersible tablets and LPV/r (2-in-1) granules in term neonates exposed to HIV, birth weights ≥2.0 to £4.0…

A RANDOMIZED TRIAL ON EARLY THERAPY IN COVID-19 HIGH-RISK OUTPATIENTS IN OMICRON ERA

Background: Antivirals and monoclonal antibodies (mAbs) were approved for early treatment of COVID-19 based on data from trials conducted in unvaccinated people before the Omicron era. The comparative effectiveness of different treatments is unknown. We present the results of the interim analysis of MONET trial (EudraCT: 2021-004188-28). Methods: In this ongoing multicenter, open-label, phase 4…

INCIDENCE AND PREDICTORS OF CLINICAL PROGRESSION IN AN EARLY TREATED COVID-19 COHORT

Background: Early treatment for preventing severe outcome of COVID-19 in high-risk not-hospitalized patients (pts) by monoclonal antibodies or antivirals represented a high-priority approach. Real-world evidence (RWE) from observational studies could give information on clinical effectiveness and predictors of treatment failure. Methods: Single-center observational study on SARS-CoV-2 pts, not requiring hospital admission but having high-risk of…